Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Aventis</strong> Strategic Brands<br />
Taxotere (docetaxel) is a chemotherapy agent<br />
primarily used to treat metastatic breast cancer<br />
and non-small-cell lung cancer (NSCLC). Launched<br />
in 1995, Taxotere is the foundation of our oncology<br />
franchise and is being studied extensively in earlystage<br />
breast, prostate, head and neck and gastric<br />
cancers.<br />
Approved indications<br />
- Second-line treatment of locally advanced or<br />
metastatic breast cancer and non-small-cell lung<br />
cancer<br />
- First-line treatment of non-small-cell lung cancer<br />
in combination with cisplatin (U.S., Europe, Japan)<br />
- Gastric, ovarian, and head and neck cancer (Japan)<br />
Major markets<br />
Taxotere is marketed in over 86 countries, and is<br />
used widely throughout Europe, the U.S. and Japan.<br />
Product features<br />
- Most widely used taxane in the U.S.<br />
- Only agent approved in Europe for use in combination<br />
with doxorubicin for fi rst-line treatment of<br />
locally advanced or metastatic breast cancer<br />
- Taxotere has demonstrated an impressive tumor<br />
response rate in locally advanced or metastatic<br />
breast cancer after failure of cytotoxic therapy, as<br />
well as prolonged patient survival<br />
- Taxotere was the fi rst taxane approved in the<br />
United States for treatment of locally advanced<br />
or metastatic breast cancer after failure of prior<br />
chemotherapy<br />
- Well-differentiated from paclitaxel<br />
>> 13
Change language